See the tardive dyskinesia (td) clinical trial results for austedo See safety info including boxed warning. See prescribing information, including boxed warning.
So tardive symptoms have a widely varying remission rate, with remission most likely in younger patients, only about 50% of the time Please see full prescribing information, including boxed warning. Tardive symptoms do not appear to become more severe in patients maintained on therapy.
See safety info and boxed warning. Tardive dyskinesia remains a significant, potentially stigmatizing or crippling adverse effect for any patient treated with an antipsychotic medication Treating tardive dyskinesia the most common option for treating td is a vesicular monoamine transporter (vmat2) inhibitor The most common adverse reactions for austedo (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis and insomnia
